GlobeNewswire
-
Avalyn to Participate in the Jefferies Global Healthcare Conference
27/05/2026 -
Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
27/05/2026 -
Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2
27/05/2026 -
Callio Therapeutics to Present Phase 1 Trial Design of CLIO-8221, Novel Dual-Payload ADC, at ASCO 2026
27/05/2026 -
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
27/05/2026 -
New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated Patients with Hypertriglyceridemia
27/05/2026 -
CDT Announces Canadian Patent for AZD5904 in Male Infertility
27/05/2026 -
Zealand Pharma to participate in the Jefferies Global Healthcare Conference
27/05/2026 -
UPDATE - Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T.™ Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine
27/05/2026 -
Simple’s Avo™ Named “Best Virtual Health Coach” in MedTech Breakthrough Awards Program
27/05/2026 -
Therini Bio Doses First Patients in Phase 1b Trial of Novel Anti-Inflammatory Therapy, THN391, for Diabetic Macular Edema
27/05/2026 -
Medicana Health Group Opens Medicana Longevity Center In Istanbul, Led By Prof. Dr. Osman Müftüoğlu
27/05/2026 -
HNL Lab Medicine Receives Accreditation from the College of American Pathologists
27/05/2026 -
Transforming Rural Health Care Through a First-of-its-Kind Collaborative
27/05/2026 -
Medline announces participation in upcoming investor conferences
27/05/2026 -
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
27/05/2026 -
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
27/05/2026 -
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
27/05/2026 -
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
27/05/2026
Pages